Skip to main
DGX
DGX logo

Quest Diagnostics (DGX) Stock Forecast & Price Target

Quest Diagnostics (DGX) Analyst Ratings

Based on 15 analyst ratings
Buy
Strong Buy 20%
Buy 20%
Hold 60%
Sell 0%
Strong Sell 0%

Bulls say

Quest Diagnostics demonstrates a strong financial performance, highlighted by a 13.1% year-over-year revenue growth to $2.82 billion, surpassing internal expectations and consensus estimates. The company has seen remarkable expansion in the physician channel, with growth of approximately 20% year-over-year, supported by increased demand for tests and healthy trends among enterprise accounts, as well as a significant 30-40% increase in consumer-initiated testing. Additionally, the total volume of tests conducted grew by 16.3% year-over-year, indicating robust operational momentum and ongoing strength in advanced diagnostics markets.

Bears say

The financial outlook for Quest Diagnostics appears negative, driven by a reported revenue per requisition decline of 0.4%, which fell short of expectations, raising concerns about growth in this key metric. Additionally, the anticipated impact of the Protecting Access to Medicare Act (PAMA) may result in a significant headwind of approximately $100 million, with uncertainty surrounding legislative outcomes further complicating the company's revenue prospects. Furthermore, the integration of the LifeLabs acquisition has not yet yielded the expected benefits, contributing to a cautious revenue trajectory despite some strength observed in organic revenue growth.

Quest Diagnostics (DGX) has been analyzed by 15 analysts, with a consensus rating of Buy. 20% of analysts recommend a Strong Buy, 20% recommend Buy, 60% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Quest Diagnostics and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Quest Diagnostics (DGX) Forecast

Analysts have given Quest Diagnostics (DGX) a Buy based on their latest research and market trends.

According to 15 analysts, Quest Diagnostics (DGX) has a Buy consensus rating as of Dec 5, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $194.07, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $194.07, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Quest Diagnostics (DGX)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.